. Author manuscript; available in PMC: 2016 Apr 1.

Published in final edited form as: Arthritis Care Res (Hoboken). 2015 Apr;67(4):457–466. doi: 10.1002/acr.22483

Table 2.

Incidence rates, unadjusted and adjusted risk of hyperlipidemia among early RA patients based on DMARD use- Full cohort

DMARD use	Sample size	Events	Follow-up (person- years)	Incidence rate and 95% CI^b (per 1000 person years)	Unadjusted HR (95% CI)	Adjusted^c HR (95% CI)
Methotrexate	7941	183	6329	28.9 (24.9–33.4)	Reference	Reference
TNF-α inhibitors^a	1010	40	1303	30.7 (21.9–41.8)	1.08 (0.76–1.52)	1.41 (0.99–2.00)
Hydroxychloroquine	6130	96	4770	20.1 (16.3–24.6)	0.70 (0.54–0.89)	0.81 (0.63–1.04)
Other non-biologic DMARDs^a	2064	45	1237	36.4 (26.5–48.7)	1.25 (0.90–1.74)	1.33 (0.95–1.84)

Abbreviations: CI- Confidence interval, DMARDs- Disease modifying anti-rheumatic drugs, HR- Hazard ratio, TNF- Tumor necrosis factor.

TNF-α inhibitors include adalimumab, certolizumab, etanercept, infliximab, and golimumab. Other non-biologic DMARDs include auranofin, injectable gold, penicillamine, sulfasalazine, minocycline, azathioprine, leflunamide, cyclophosphamide and cyclosporine.

95% confidence interval derived from Poisson distribution.

Adjusted for age, gender, cardiovascular risk factors and comorbidities, cardiovascular drug use, pain medications and healthcare use in the prior year in a cox proportional hazard regression model.